C

Conception

Develops iPSC-derived egg cells for fertility

Senior Scientist - Organoid

Full-Time
No salary listed
Senior, Expert
PhD
Berkeley, CA, USA
In Person
Biology & BiotechTranslational Research & Bench Biology

About the job

Requirements
  • The candidate must have a PhD in a relevant field, plus postdoctoral training or equivalent industry experience.
  • The candidate must have a strong track record of personally building or substantially improving complex organoid, tissue, or differentiation systems.
  • The candidate must have a deep understanding of cell-cell interactions and how the microenvironment shapes tissue development and function.
  • The candidate must demonstrate exceptional hands-on troubleshooting and experimental judgment.
  • The candidate must be able to set scientific direction, prioritize clearly, and turn complex data into actionable next steps.
  • The candidate must be a clear communicator who is highly organized, keeps strong records, and works well across teams.
  • The candidate must have a strong work ethic and willingness to stay close to the bench, including routine work when needed.
  • The candidate must be able to learn quickly and work effectively in a fast-moving startup environment.
Responsibilities
  • Own the scientific strategy and day-to-day development of the ovarian organoid and follicle niche systems.
  • Design and build new differentiation and tissue engineering approaches that support follicle formation, growth, maturation, and oocyte competence.
  • Identify the main biological and technical bottlenecks, prioritize the highest-value experiments, and systematically improve the system.
  • Establish quantitative, stage-specific, and functional readouts that distinguish meaningful biological progress from marker expression alone.
  • Remain deeply hands-on and close to the cultures, experiments, and data.
  • Work closely with cross-functional teams to integrate complementary approaches and advance shared scientific goals.
  • Mentor and develop scientists while setting a high bar for rigor, documentation, pace, and scientific thinking.
  • Help build a team culture grounded in curiosity, urgency, flexibility, technical excellence, and transparency.
Desired Qualifications
  • Experience in reproductive biology, ovarian development, or germ cell biology is a plus.

About the company

Conception.bio develops fertility treatments by turning a person’s blood cells into mature egg cells using induced pluripotent stem cell (iPSC) technology. Blood is collected, reprogrammed into iPSCs, and guided to become viable eggs that can be used for reproduction, with optional genetic screening of embryos. It differentiates itself by producing patient-derived eggs from blood and selling directly to consumers, bypassing traditional clinic pathways. The goal is to broaden access to fertility options by enabling later-life parenting and embryo genetic screening through a patient-derived egg platform with a direct-to-consumer model.

Company Size

51-200

Company Stage

Early VC

Total Funding

$20M

Headquarters

Berkeley, California

Founded

2017

Get referred to Conception

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 milestone brought major press and validated technical traction after years of secrecy.
  • Senior-scientist hiring in May 2026 signals continued team-building around 3D organoid development.
  • Conception still claims a broad fertility market: infertility, age-related decline, and same-sex parenthood.

What critics are saying

  • Conception itself says clinical trials remain years away, with safety thresholds still unmet.
  • Lancaster University and Nuffield highlighted unresolved consent, parenthood, and child-rights issues in 2025.
  • U.S. and European regulators can block IVG commercialization for years, starving Conception before revenue.

What makes Conception unique

  • Conception generated stem-cell-derived primary oocytes in June 2026, not just embryo models.
  • Its blood-draw-to-mini-ovary workflow targets patient-specific eggs from iPSCs, unlike donor-egg clinics.
  • Few competitors pursue human in vitro gametogenesis with a direct-to-consumer fertility model.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Company Equity
  • Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%
The Bridge
Aug 18th, 2022
不妊治療にイノベーション、Ips細胞由来卵子を開発するDioseve(ディオシーヴ)が4億円をシード調達

iPS 細胞については、山中伸弥氏(現在、京都大学 iPS 細胞研究所長・教授)が2012年にノーベル医学・生理学賞を受賞したことを契機に、我々も日常的に耳にするようになった。iPS 細胞の日本語での正式名称は人工多能性幹細胞、つまり、そこからヒト(ヒトに限らず、あらゆる生物に適用可能だが)のあらゆる身体部位の細胞に変化させられる細胞のことだ。事故や病気などで損傷や摘出した臓器や組織の再生医療の分野で注目を集めている。. 倫理的課題はあるものの、この iPS 細胞から卵子(卵細胞)を作製することができれば、妊娠や生殖にまつわる多くの問題を解決することができるだろう。まず、卵子の老化・閉経・排卵障害といった問題を回避できるため、女性は何歳でも妊娠できるようになる。子宮に問題があっても、受精卵を預かってくれる代理母を見つけられれば、生まれてくる子供は自分の遺伝子を受け継ぐことになる。男性からも卵子を作製できるから、男性同士のカップルも子供の biological parents になれるのだ。

Brownstone Research
Nov 23rd, 2021
Conception Raises $20 Million VC Round - Brownstone Research

This is going to be a massive moral and ethical debate in the coming years…